Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives
Yumeng Wang, Guiling Li
Frontiers of Medicine (2019) Vol. 13, Iss. 4, pp. 438-450
Closed Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

A Pan-Cancer Bioinformatic Analysis of RAD51 Regarding the Values for Diagnosis, Prognosis, and Therapeutic Prediction
Hengrui Liu, Jieling Weng
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 53
A comprehensive bioinformatic analysis of cyclin-dependent kinase 2 (CDK2) in glioma
Hengrui Liu, Jieling Weng
Gene (2022) Vol. 822, pp. 146325-146325
Closed Access | Times Cited: 48
A bioinformatic study of IGFBPs in glioma regarding their diagnostic, prognostic, and therapeutic prediction value.
Hengrui Liu, Tao Tang
PubMed (2023) Vol. 15, Iss. 3, pp. 2140-2155
Closed Access | Times Cited: 28
High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay in Human Cervical Cancer: Recent Evidence and Future Directions
Soumaya Allouch, Ahmed Malki, Asma Allouch, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 63
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
Xin Cai, Huajie Zhan, Yuguang Ye, et al.
Frontiers in Genetics (2021) Vol. 12
Open Access | Times Cited: 50
PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed
Weijia Huang, Jiewei Liu, Kai Xu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 24
Immunotherapy for HPV associated cancer
Ian H. Frazer, Janin Chandra
Papillomavirus Research (2019) Vol. 8, pp. 100176-100176
Open Access | Times Cited: 37
The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix
Georgia Karpathiou, Céline Chauleur, Mousa Mobarki, et al.
Pathology - Research and Practice (2019) Vol. 216, Iss. 1, pp. 152782-152782
Open Access | Times Cited: 37
Immunotherapy in cervical cancer: An evolutionary paradigm in women's reproductive health
Mansi Damani, Akshada Mhaske, Sayali Dighe, et al.
Critical Reviews in Therapeutic Drug Carrier Systems (2025) Vol. 42, Iss. 3, pp. 55-88
Closed Access
Efficacy and safety of immunotherapy in cervical cancer: a review of advances in immune-related therapy for cervical cancer
Jing Liu, Yaxin Kang, Li Li, et al.
Holistic Integrative Oncology (2025) Vol. 4, Iss. 1
Open Access
Prognostic Implications of Immune-Related Genes’ (IRGs) Signature Models in Cervical Cancer and Endometrial Cancer
Hao Ding, Guanlan Fan, Yuexiong Yi, et al.
Frontiers in Genetics (2020) Vol. 11
Open Access | Times Cited: 31
In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1
Daniel Rubins, Xiangjun Meng, Paul McQuade, et al.
Molecular Imaging and Biology (2020) Vol. 23, Iss. 2, pp. 241-249
Closed Access | Times Cited: 31
iTRAQ-based quantitative proteomic analysis of the inhibition of cervical cancer cell invasion and migration by metformin
Chenglai Xia, Fang Yang, Zhihong He, et al.
Biomedicine & Pharmacotherapy (2019) Vol. 123, pp. 109762-109762
Open Access | Times Cited: 30
Monoclonal antibodies in cervical malignancy-related HPV
Parisa Shiri Aghbash, Nima Hemmat, Hamidreza Fathi, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 16
Cervical cancer immune infiltration microenvironment identification, construction of immune scores, assisting patient prognosis and immunotherapy
Shijie Yao, Liyang Zhao, Siming Chen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Advances in the application of immune checkpoint inhibitors in gynecological tumors
YingGang Zou, Ying Xu, XiaoChen Chen, et al.
International Immunopharmacology (2023) Vol. 117, pp. 109774-109774
Closed Access | Times Cited: 10
Relationship and prognostic significance of IL-33, PD-1/PD-L1, and tertiary lymphoid structures in cervical cancer
Ying Zhang, Jing Li, Fan Yang, et al.
Journal of Leukocyte Biology (2022) Vol. 112, Iss. 6, pp. 1591-1603
Closed Access | Times Cited: 14
Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer
Shuping Yin, Han Cui, Shuang Qin, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 166, pp. 115355-115355
Open Access | Times Cited: 7
Nanomedicine-Mediated Optimization of Immunotherapeutic Approaches in Cervical Cancer
Jeaneen Venkatas, Moganavelli Singh
Nanomedicine (2021) Vol. 16, Iss. 15, pp. 1311-1328
Open Access | Times Cited: 17
LOXL2 small molecule inhibitor restrains malignant transformation of cervical cancer cells by repressing LOXL2-induced epithelial-mesenchymal transition (EMT)
Ting Peng, Shitong Lin, Yifan Meng, et al.
Cell Cycle (2022) Vol. 21, Iss. 17, pp. 1827-1841
Open Access | Times Cited: 10
Immunology of Cervical Cancer
Joaquín Manzo-Merino, Susana del-Toro-Arreola, Leticia Rocha‐Zavaleta, et al.
Revista de investigaci�n Cl�nica (2020) Vol. 72, Iss. 4
Open Access | Times Cited: 15
Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway
Lili Song, Shikai Liu, Sufen Zhao
Bioengineered (2022) Vol. 13, Iss. 4, pp. 11240-11257
Open Access | Times Cited: 9
The expression and significance of PD‐L1 in condyloma acuminatum
Yamei Liu, Weiqi Huang, Kun Yang, et al.
Skin Research and Technology (2024) Vol. 30, Iss. 1
Open Access | Times Cited: 1
Gq/G11 oncogenic mutations promote PD-L1 expression and suppress tumor immunity
Jingyan Dong, Yue Xu, Dawei Yu, et al.
European Journal of Cell Biology (2024) Vol. 103, Iss. 4, pp. 151467-151467
Open Access | Times Cited: 1
The potential role of HPV oncoproteins in the PD-L1/PD-1 pathway in cervical cancer: new perspectives on cervical cancer immunotherapy
Jin Li, Yuhong Ma, Qing-Feng Wu, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top